Rubius Therapeutics, Inc. Price Chart
Rubius Therapeutics, Inc. 5RT.F Financial and Trading Overview
| Rubius Therapeutics, Inc. stock price | 0.01 EUR |
| Previous Close | 0.01 EUR |
| Open | 0.01 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 0.01 - 0.01 EUR |
| 52 Week Range | 0.01 - 5.35 EUR |
| Volume | 630 EUR |
| Avg. Volume | 12 EUR |
| Market Cap | 3.23M EUR |
| Beta (5Y Monthly) | 2.385982 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.4 EUR |
5RT.F Valuation Measures
| Enterprise Value | -12589829 EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.005394191 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.077844314 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.104 |
Trading Information
Rubius Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 2.385982 |
| 52-Week Change | -99.75% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.35 EUR |
| 52 Week Low | 0.01 EUR |
| 50-Day Moving Average | 0.18 EUR |
| 200-Day Moving Average | 1.54 EUR |
5RT.F Share Statistics
| Avg. Volume (3 month) | 12 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 90.48M |
| Float | 85.39M |
| Short Ratio | N/A |
| % Held by Insiders | 5.49% |
| % Held by Institutions | 53.68% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.63% |
| Return on Equity (ttm) | -185.30% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -120995000 EUR |
| Net Income Avi to Common (ttm) | -179666000 EUR |
| Diluted EPS (ttm) | -0.77 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 14.87M EUR |
| Total Cash Per Share (mrq) | 0.16 EUR |
| Total Debt (mrq) | 1.1M EUR |
| Total Debt/Equity (mrq) | 7.27 EUR |
| Current Ratio (mrq) | 2.544 |
| Book Value Per Share (mrq) | 0.167 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -150142000 EUR |
| Levered Free Cash Flow (ttm) | -85372000 EUR |
Profile of Rubius Therapeutics, Inc.
| Country | Germany |
| State | MA |
| City | Foxborough |
| Address | 124 Washington Street |
| ZIP | 02035 |
| Phone | 508 543 1720 |
| Website | https://www.rubiustx.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 6 |
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Q&A For Rubius Therapeutics, Inc. Stock
What is a current 5RT.F stock price?
Rubius Therapeutics, Inc. 5RT.F stock price today per share is 0.01 EUR.
How to purchase Rubius Therapeutics, Inc. stock?
You can buy 5RT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Rubius Therapeutics, Inc.?
The stock symbol or ticker of Rubius Therapeutics, Inc. is 5RT.F.
How many shares does Rubius Therapeutics, Inc. have in circulation?
The max supply of Rubius Therapeutics, Inc. shares is 248.51M.
What is Rubius Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Rubius Therapeutics, Inc. PE Ratio is 0.00000000 now.
What was Rubius Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Rubius Therapeutics, Inc. EPS is 0 EUR over the trailing 12 months.